Allianz Asset Management
KRYS icon

Allianz Asset Management’s Krystal Biotech KRYS Stock Holding History

Allianz Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$491K Hold
1,900
– – ﹤0.01% 1841
2025
Q4 		$468K Buy
+1,900
New +$400K ﹤0.01% 1845
2025
Q2 		– Sell
-3,715
Closed -$670K – 2167
2025
Q1 		$670K Sell
3,715
-387
-9% -$65.1K ﹤0.01% 1786
2024
Q4 		$643K Buy
4,102
+1,500
+58% +$266K ﹤0.01% 1783
2024
Q3 		$474K Sell
2,602
-1,410
-35% -$272K ﹤0.01% 1865
2024
Q2 		$737K Sell
4,012
-546
-12% -$91.7K ﹤0.01% 1701
2024
Q1 		$811K Buy
4,558
+158
+4% +$21.9K ﹤0.01% 1481
2023
Q4 		$546K Hold
4,400
– – ﹤0.01% 1831
2023
Q3 		$510K Sell
4,400
-2,000
-31% -$244K ﹤0.01% 1915
2023
Q2 		$751K Sell
6,400
-1,200
-16% -$123K ﹤0.01% 1627
2023
Q1 		$608K Sell
7,600
-4,800
-39% -$377K ﹤0.01% 1846
2022
Q4 		$982K Sell
12,400
-50
-0.4% -$3.71K ﹤0.01% 1527
2022
Q3 		$867K Sell
12,450
-45,239
-78% -$3.27M ﹤0.01% 1436
2022
Q2 		$3.79M Buy
57,689
+27,809
+93% +$1.73M ﹤0.01% 1192
2022
Q1 		$1.99M Buy
29,880
+8,721
+41% +$544K ﹤0.01% 1593
2021
Q4 		$1.48M Buy
+21,159
New +$1.23M ﹤0.01% 1732
2021
Q3 		– Sell
-7,859
Closed -$534K – 2595
2021
Q2 		$534K Buy
7,859
+6
+0.1% +$419 ﹤0.01% 2006
2021
Q1 		$605K Sell
7,853
-106
-1% -$7.71K ﹤0.01% 1824
2020
Q4 		$478K Sell
7,959
-47
-0.6% -$2.35K ﹤0.01% 1646
2020
Q3 		$344K Sell
8,006
-699
-8% -$30.4K ﹤0.01% 1682
2020
Q2 		$361K Sell
8,705
-12,947
-60% -$623K ﹤0.01% 2152
2020
Q1 		$937K Sell
21,652
-9,583
-31% -$501K ﹤0.01% 1824
2019
Q4 		$1.73M Buy
31,235
+5,759
+23% +$283K ﹤0.01% 1933
2019
Q3 		$891K Buy
25,476
+95
+0.4% +$4.25K ﹤0.01% 2173
2019
Q2 		$1.02M Sell
25,381
-9,874
-28% -$323K ﹤0.01% 2129
2019
Q1 		$1.16M Buy
+35,255
New +$831K ﹤0.01% 2040

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allianz Asset Management's KRYS Position: Q1 2026 in Review

Allianz Asset Management held its Krystal Biotech (KRYS) position steady in Q1 2026 at 1,900 shares worth $491K. The position accounts for ﹤0.01% of the portfolio, ranked #1841.

Allianz Asset Management first reported a position in KRYS in Q1 2019 and has held it in 26 quarters since. The position peaked at $3.79M in Q2 2022. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Allianz Asset Management held 1,900 shares of Krystal Biotech worth $491K as of Q1 2026.
  • Allianz Asset Management left its Krystal Biotech share count unchanged in Q1 2026.
  • Krystal Biotech made up ﹤0.01% of Allianz Asset Management's portfolio in Q1 2026, its #1841 holding.
  • Allianz Asset Management first reported a position in Krystal Biotech in Q1 2019 and has held it in 26 quarters since.
  • Allianz Asset Management's Krystal Biotech position peaked at $3.79M in Q2 2022.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.